Candel is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Candel’s engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. Candel has established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs. CAN-2409 is the lead product candidate from the adenovirus platform, and CAN-3110 is the lead product candidate from the HSV platform.
Company profile
Ticker
CADL
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Sana Biotechnology • Ginkgo Bioworks • Exelixis ...
SEC CIK
Corporate docs
Subsidiaries
Candel Therapeutics Securities Corporation ...
IRS number
522214851
CADL stock data
Analyst ratings and price targets
Latest filings (excl ownership)
ARS
2022 FY
Annual report to shareholders
23 May 23
DEF 14A
Definitive proxy
23 May 23
8-K
Regulation FD Disclosure
19 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
11 May 23
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
9 May 23
8-K
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Non-Small Cell Lung Cancer
17 Apr 23
S-8
Registration of securities for employees
30 Mar 23
10-K
2022 FY
Annual report
30 Mar 23
Latest ownership filings
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | |
|---|---|---|---|
| Revenue | |||
| Cost of revenue | |||
| Operating income | |||
| Operating margin | |||
| Net income | |||
| Net profit margin | |||
| Cash on hand | |||
| Change in cash | |||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 59.52 mm | 59.52 mm | 59.52 mm | 59.52 mm | 59.52 mm | 59.52 mm |
| Cash burn (monthly) | 3.60 mm | 2.94 mm | 3.21 mm | 2.95 mm | 3.61 mm | 2.85 mm |
| Cash used (since last report) | 7.60 mm | 6.20 mm | 6.78 mm | 6.22 mm | 7.61 mm | 6.01 mm |
| Cash remaining | 51.93 mm | 53.33 mm | 52.75 mm | 53.30 mm | 51.91 mm | 53.51 mm |
| Runway (months of cash) | 14.4 | 18.2 | 16.4 | 18.1 | 14.4 | 18.8 |
Institutional ownership, Q4 2022
24.5% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 21 |
| Opened positions | 2 |
| Closed positions | 5 |
| Increased positions | 5 |
| Reduced positions | 6 |
| 13F shares | Current |
|---|---|
| Total value | 7.98 bn |
| Total shares | 7.09 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Northpond Ventures | 1.94 mm | $3.46 bn |
| Northpond Ventures | 1.69 mm | $0.00 |
| BEN Franklin Resources | 1.13 mm | $2.01 bn |
| Sands Capital Ventures | 811.74 k | $1.45 mm |
| FMR | 737.60 k | $1.32 bn |
| Vanguard | 405.76 k | $726.30 mm |
| Bridgeway Capital Management | 132.70 k | $237.53 mm |
| Geode Capital Management | 131.20 k | $234.00 k |
| BLK Blackrock | 39.05 k | $69.89 mm |
| STT State Street | 27.60 k | $49.40 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 28 Apr 23 | Jason Amello | Stock Option Common Stock | Grant | Acquire A | No | No | 1.29 | 90,000 | 116.10 k | 90,000 |
| 28 Apr 23 | Francesca Barone | Stock Option (Right to Biuy) Common Stock | Grant | Acquire A | No | No | 1.29 | 90,000 | 116.10 k | 90,000 |
| 28 Apr 23 | Garrett Nichols | Stock Option Common Stock | Grant | Acquire A | No | No | 1.29 | 45,000 | 58.05 k | 45,000 |
| 28 Apr 23 | Seshu Tyagarajan | Stock Option Common Stock | Grant | Acquire A | No | No | 1.29 | 90,000 | 116.10 k | 90,000 |
| 28 Apr 23 | Paul Peter Tak | Stock Option Common Stock | Grant | Acquire A | No | No | 1.29 | 180,000 | 232.20 k | 180,000 |
News
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $11 Price Target
22 May 23
Candel Therapeutics Says One Dose Of CAN-3110 Shows Encouraging Responses In A Type Of Brain Cancer
19 May 23
BMO Capital Maintains Outperform on Candel Therapeutics, Lowers Price Target to $3
15 May 23
Candel Therapeutics: Q1 Earnings Insights
11 May 23
Candel Therapeutics Q1 EPS $(0.30) Down From $(0.03) YoY; Cash And Cash Equivalents Of $59.3M Will Be Sufficient To Fund Current Operating Plan Into Q2 2024
11 May 23
Press releases
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
19 May 23
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
11 May 23
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
17 Apr 23
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
30 Mar 23